Anticoagulant Drugs Market Size, Share, Growth and Industry Analysis, By Type (NOACs, Heparin, Warfarin and Others), By Application (Hospital, Pharmacy and Others), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

ANTICOAGULANT DRUGS MARKET OVERVIEW

In 2024, the anticoagulant drugs market size reached a value of USD 33.76 billion, and it is projected to surge to USD 51.48 billion by 2033, CAGR of 4.8% during the forecast period from 2025 To 2033.

Over the course of the world, the prevalence of chronic diseases is increasing at an alarming rate. The burden of disease as a whole is being influenced by elements including obesity, bad lifestyle choices, and high stress. Blood clots, which can cause a heart attack or other significant consequences in people with coronary artery disease (CAD), are prevented and treated using anticoagulant drugs in these patients. According to research from the Centers for Disease Control & Prevention (CDC) in the United States, coronary heart disease is one of the most prevalent types of heart conditions in the nation. Anticoagulant drugs are now more frequently consumed in order to reduce these disorders' negative effects. A considerable fraction of adults are experiencing health problems because of stress and other contributing factors, and the occurrence of myocardial infarction is also rising globally.

COVID-19 IMPACT

Negligible Effect of the Pandemic on the Production of the Drugs Because of its Requirement to Treat Patients

The COVID-19 pandemic appeared to have a negligible effect on the expansion of the worldwide market, despite the fact that lockdown measures caused supply chain interruptions. Evidently, there has been a marked rise in the incidence of venous thromboembolism (VTE) among COVID-19 patients. According to the WHO's recommendation from January 2021, patients with COVID-19, whether they have it verified or not, must have accessibility to follow-up therapy with low-dose anticoagulant drugs. The use of these medications has been encouraged by such circumstances. But as the number of people with heart conditions continues to climb, more generic medications will be developed, which will in part impact the sales of goods from major producers like heparin.

LATEST TRENDS

Growing Geriatric Population and Spike in Demand for Innovative Treatments Presents a Strong Potential for the Expansion of the Market

The market for anticoagulant pharmaceuticals is poised for growth as a result of the expanding use of novel oral anticoagulants (NOACs) and rising consumer awareness of these medications in emerging countries. Along with the growing geriatric population, a spike in demand for innovative treatments is anticipated to fuel market expansion. The projection year has presented a strong potential for the market to expand due to the rising frequency of cardiovascular diseases and venous thromboembolism (VTE).

Request a Free sample to learn more about this report

ANTICOAGULANT DRUGS MARKET SEGMENTATION

By Type

Based on type, the market is distributed into NOACs, Heparin, Warfarin and Others

By Application

Based on application, the market is divided into Hospital, Pharmacy and Others.

DRIVING FACTORS

Better Access to Medication with Hospitals In-House Pharmacies Promote the Sale of these Drugs

According to the distribution channel, the hospital pharmacy segment accounted for approximately 53% of the anticoagulant drugs market in 2021. There are many advantages to hospital pharmacy, including better access to medications. Many patients with cardiovascular disease (CVD) visit hospital outpatient departments (OPDs) to receive treatment and receive prescriptions for medications due to the improved infrastructure and larger number of medical staff. Anticoagulant drugs sales within in-house pharmacies will increase at a large rate as more patients choose to have their treatments at hospitals in order to receive high-quality care.

Use of the Heparin Drug by Cardiac Surgeons to Treat Patients with Various Medical Disorders

Heparin, factor Xa inhibitors, warfarin, and direct thrombin inhibitor medications make up the different segments of the anticoagulant drugs industry. Heparin is a medication primarily used to stop blood clots from forming in a variety of individuals. This blood thinner is used by cardiac surgeons to treat a number of medical disorders, including deep vein thrombosis, acute coronary syndrome, atrial fibrillation, pulmonary embolism, and unstable angina.

RESTRAINING FACTORS

Excessive Bleeding and other Increased Risk Associated with this Medication can Obstruct with the Growth of the Market

The development of the global anticoagulant drugs market growth over the forecast period may be hampered by the adverse effects of anticoagulant drugs or blood thinners. Excessive bleeding is the main negative side effect of taking these medications. A common instance is the anticoagulant medicine warfarin, which also carries an increased risk of other side effects such dermal necrosis, purple or blue toes, congenital impairments, and miscarriages. Anticoagulant medications are typically not recommended for persons with atrial fibrillation (AFib), elevated blood pressure, and other conditions to prevent problems.

• Request a Free sample to learn more about this report

•  

ANTICOAGULANT DRUGS MARKET REGIONAL INSIGHTS

Growing Elderly Population and Medical Deals Between Governments and Health Institutions help Europe in Leading the Market

During the projection period, it is predicted that the anticoagulant drugs market share in Europe would surpass that of the other regions. The number of old people is rising noticeably. The World Bank estimates that 21.98% of Germany's population was 65 years of age or older in 2021. The need for anticoagulants has increased as a result of this issue. The elderly population in the area is becoming more and more in need of non-invasive, improvised treatments. A positive increase in new medication deals involving governments and healthcare institutions is also being seen in the region.

KEY INDUSTRY PLAYERS

Introduction of New Products by the Major Players to Maintain their Strong Market Presence

To strengthen their competitive advantage, the companies in the anticoagulant drugs sector are introducing new products. For instance, Boehringer Ingelheim announced in June 2021 that the U.S. FDA has approved its Pradaxa (dabigatran etexilate) oral tablets to treat venous thromboembolism in children between the ages of 3 months and 12 years (VTE). The manufacturers' ability to increase their global presence will be enabled by similar tactics.

List of Top Anticoagulant Drugs Companies

• Bristol-Myers Squibb (U.S.)
• Bayer (Germany)
• Pfizer (U.S.)
• Johnson & Johnson (U.S.)
• Sanofi (France)
• Boehringer Ingelheim (Germany)
• Daiichi Sankyo (Japan)

REPORT COVERAGE

This report covers the anticoagulant drugs market. The CAGR expected to be in during the forecast period, and also the USD value in 2021 and what it is expected to be in 2031. The effect COVID-19 had on the market in the beginning of the pandemic. The latest trends taking place in this industry. The factors that are driving this market as well as the factors that are restraining the growth of industry. The segmentation of this market based on type and applications. The region leading in the industry and why they will continue to do so during the forecast period. Further, the key market players, what all is being done by them to stay ahead of their competition as well as retain their market positions. All these details are covered in the report.